234 results
8-K
EX-99.1
SAVA
Cassava Sciences Inc
10 May 24
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
4:07pm
, intended purpose, or future results of our on-going Phase 3 program of simufilam in patients with Alzheimer's disease; the timing of anticipated milestones
8-K
EX-99.1
SAVA
Cassava Sciences Inc
1 May 24
Other Events
9:13am
while protecting stockholders from excessive dilution; the design, scope, completion, intended purpose, or future results of our warrant distribution
8-K
EX-99.1
SAVA
Cassava Sciences Inc
15 Apr 24
Redemption Date Announced for Warrants
4:01pm
, completion, intended purpose, or future results of our warrant distribution; any expected clinical results of our on-going Phase 3 studies
8-K
EX-99.1
67w 60zts2m1l515wi
28 Feb 24
Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
9:22am
8-K
EX-99.1
dgqfo7wownonjc
7 Feb 24
No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
9:20am
424B2
wxb8pc
3 Jan 24
Prospectus for primary offering
4:22pm
8-A12B
EX-4.1
5idfyg2
3 Jan 24
Registration of securities on exchange
4:18pm
8-K
EX-4.1
u9ta5eh8
3 Jan 24
Entry into a Material Definitive Agreement
9:10am
8-A12G
EX-4.1
8a5moxsjb
2 Jan 24
Registration of securities
9:10am
8-K
EX-99.1
3xwr8
12 Dec 23
Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders
9:19am
8-K
EX-99.2
7ghwub1j
12 Dec 23
Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders
9:19am
8-K
EX-99.1
lhn76
7 Nov 23
Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
9:08am
8-K
EX-3.4
jkokqyd1 yw5qbob
13 Sep 23
Amendments to Articles of Incorporation or Bylaws
4:17pm